Alios BioPharma, developer of anti-viral therapies, has tacked $8 million onto its first round of funding, bringing its total to $32 million. The new money came solely from SR One. Based in South San Francisco, the company plans to use the money to push its lead compound past phase-one trials.
Alios brought in the initial $24 million from Novartis Ventures, Novo AS and Roche Venture Fund.